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Abstract
Quiescent hepatic stem cells (HSCs) can be activated when hepatocyte proliferation is compromised. Chemical injury rodent
models have been widely used to study the localization, biomarkers, and signaling pathways in HSCs, but these models
usually exhibit severe promiscuous toxicity and fail to distinguish damaged and non-damaged cells. Our goal is to establish
new animal models to overcome these limitations, thereby providing new insights into HSC biology and application. We
generated mutant mice with constitutive or inducible deletion of Damaged DNA Binding protein 1 (DDB1), an E3 ubiquitin
ligase, in hepatocytes. We characterized the molecular mechanism underlying the compensatory activation and the
properties of oval cells (OCs) by methods of mouse genetics, immuno-staining, cell transplantation and gene expression
profiling. We show that deletion of DDB1 abolishes self-renewal capacity of mouse hepatocytes in vivo, leading to
compensatory activation and proliferation of DDB1-expressing OCs. Partially restoring proliferation of DDB1-deficient
hepatocytes by ablation of p21, a substrate of DDB1 E3 ligase, alleviates OC proliferation. Purified OCs express both
hepatocyte and cholangiocyte markers, form colonies in vitro, and differentiate to hepatocytes after transplantation.
Importantly, the DDB1 mutant mice exhibit very minor liver damage, compared to a chemical injury model. Microarray
analysis reveals several previously unrecognized markers, including Reelin, enriched in oval cells. Here we report a genetic
model in which irreversible inhibition of hepatocyte duplication results in HSC-driven liver regeneration. The DDB1 mutant
mice can be broadly applied to studies of HSC differentiation, HSC niche and HSCs as origin of liver cancer.
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Introduction
Stem cells can self-renew, differentiate, and maintain tissue
homeostasis. In highly proliferating tissues such as the skin and the
gut, stem cells continuously produce transit-amplifying cells that
differentiate and replenish short-lived mature cells [1,2]. By
contrast, the liver has very low levels of cell turnover, and it
primarily relies on replication of highly differentiated parenchymal
hepatocytes to regenerate in response to loss of liver mass [3,4,5].
However, when hepatocyte replication is inhibited or compro-
mised, quiescent HSCs can be activated to produce a large
number of transit-amplifying progenitor cells (called OCs in
rodents), which eventually differentiate to hepatocytes and bile
duct cholangiocytes to restore the liver to its original volume
[6,7,8].
Conventionally, HSC activation and oval cell proliferation are
induced in chemical injury rodent models [6,9,10]. One of the
commonly used methods is the 2-acetylaminofluorene (2-AAF)/
partial hepatectomy (PH) model, in which hepatocyte proliferation
is blocked by 2-AAF prior to PH-stimulated liver regeneration
[11]. This rodent model is well established in rats, but the same
procedure does not induce OCs in mice. Alternative protocols
such as 3,5-diethoxycarbonyl-1,4-dihydro-collidine (DDC)-supple-
mented diets and ethionine-supplemented choline-deficient diets
have been developed to induce HSC activation in mice [12,13].
However, these injury models are not ideal for identifying
biomarkers of HSCs or studying mechanisms of HSC activation
for several reasons. First, these chemicals damage both hepatocytes
and non-parenchymal cells including HSCs and OCs. Second, it is
impossible to genetically distinguish damaged existing hepatocytes
from newly regenerated hepatocytes from activated HSCs. Finally,
promiscuous effects of the chemicals would confound experimental
result interpretation. As a result, a better model bypassing these
difficulties is desirable.
The molecular signals that activate HSCs are just beginning to
be addressed in transgenic mice. Overexpression of TWEAK
(TNF-like weak inducer of apoptosis), a TNF-family cytokine, can
stimulate oval cell proliferation in mouse liver through binding its
receptor Fn-14 [14]. Similarly, hepatocyte-specific deletion
of the neurofibromatosis type 2 (Nf2) tumor suppressor gene yields a
progressive expansion of oval cells [15]. However, whether and
how TWEAK or merlin (encoded by Nf2) directly stimulates the
oval cell proliferation still need to be established.
We recently demonstrated that hepatocyte-specific deletion of
DDB1, an adaptor protein for Cullin4 ubiquitin ligase [16],
permanently blocks the hepatocytes from self-renewing, resulting
in compensatory regeneration of new DDB1-expressing hepato-
cytes and progressive tumor development [17]. Here we report
that one possible source of these new hepatoctyes are the DDB1-
expressing oval cells, which are activated in response to the
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mutant mice show minor liver damage compared with those
chemically injured mice. We have explored this model of HSC
activation and identified several candidate markers of oval cells
that have not been unraveled using chemical injury models.
Materials and Methods
Animals
Generation and characterization of DDB1
F/F and DDB1
F/F;
Mx1-Cre
+/2 mice have been described previously [17]. Alb-Cre
strain, p21 mutant strain and Rosa26-lacZ Cre-reporter strain were
purchased from The Jackson Laboratory (Bar Harbor, ME) [18].
Immunocompromised 6-week-old nu/nu mice were purchased
from the Harlan Laboratories (Indianapolis, IN). The diet
containing 0.1% DDC was purchased from Purina TestDiet
(Richmond, IN). All animals were maintained in pathogen-free
facilities and all experiments followed regulations of the investi-
gators’ institutional animal care, with approval ID 08-061 from the
Sanford-Burnham Medical Research Institute review committee.
Immunostaining and Imaging
Tissue samples were dissected from mice and fixed in 4% (w/v)
paraformaldehyde, embedded in paraffin, and immunostaining
were performed as described [19]. The following primary
antibodies were diluted in Antibody Diluent with Background
Reducing Components (Dako, Denmark) and incubated at 4uC
overnight: DDB1 (Bethyl Laboratories, Burlingame, CA), EpCAM
(epithelial cell adhesion molecule) (Abcam, Cambridge, MA), A6
(gift from Dr. V. Factor), Cytokeratin19 (CK19) (gift from Dr. R.
Oshima), Albumin (Novus Biologicals, Littleton, CO), a-fetopro-
tein (AFP) (Santa Cruz Biotechnology, Santa Cruz, CA), CD133
(eBioscience, San Diego, CA), ß-galactosidase (Mirus Bio Corpo-
ration, Madison, WI), CD45 (eBioscience), F4/80 (eBioscience)
and Reelin (Abcam).
For immunocytochemical staining, cells were fixed with PBS
containing 4% paraformaldehyde at room temperature for
20 minutes and permeabilized and blocked with blocking buffer
containing 0.1% Triton X, 1% BSA and 10% goat serum at room
temperature for 30 minutes. Cells were then incubated with
primary antibodies at 4uC overnight, followed by secondary
antibodies at room temperature for 30 minutes.
Western Blotting
Hepatocytes isolated after perfusion were lysed in RIPA buffer
and lysates were centrifuged at 12,000 rpm for 15 minutes at 4uC
to remove cellular debris. Supernatants were diluted in NuPAGE
sample buffer (Invitrogen, Carlsbad, CA) and boiled at 70uC for
10 minutes. Protein samples were separated by NuPAGE precast
gel (Invitrogen) according to the manufacturer’s instruction and
transferred to PVDF membranes. The following primary anti-
bodies were incubated overnight at 4uC: p21 (BD Biosciences,
Bedford, MA), c-Jun (Santa Cruz Biotechnology), DDB1 (Invitro-
gen), Lamin B, PCNA and ß-tubulin (Sigma-Aldrich, St. Louis,
MO).
Cell Fractionation
DDB1-deficient mouse embryonic fibroblasts (MEFs) were
obtained by infecting primary DDB1
F/F MEFs with adenovirus
expressing Cre [19]. Cells were suspended in HB buffer (10 mM
Tris, pH8.0, 1.5 mM MgCl2, 10 mM KCl, protease inhibitors
cocktail) and allowed to swell on ice for 15 min. Triton X-100
(0.2%) was added and the homogenate was centrifuged for 10 min
at 1000 g at 4uC. The supernatant (cytoplasmic fraction) was
transferred to fresh tube and NaCl concentration was adjusted to
200 mM. Nuclear pellet was washed 5 times with HB buffer
containing 0.2% Triton X-100 and resuspended by vortexing at
4uC for 30 minute in buffer C (10 mM Tris, pH8.0, 1.5 mM
MgCl2, 10 mM KCl, 400 mM NaCl, 0.4% Triton X-100,
protease inhibitors cocktail). Homogenate was then centrifuged
for 15 min at 20,000 g at 4uC and the nuclear extract was
transferred to a fresh tube. Equal volumes of HB buffer were
added to bring the NaCl concentration to 200 mM.
Liver Cell Isolation
Liver cells were isolated using a standard three-step protocol.
Liver perfusion was initiated by administering through the portal
vein 200 ml of 0.5 M EGTA solution in basic liver perfusion
buffer (30 mM KCl, 1.3 M NaCl, 10 mM NaH2PO4.2H2O,
100 mM Glucose and 100 mM HEPES, adjusted to pH7.4 at
37uC). The liver was then washed with 200 ml of basic liver
perfusion buffer alone. Subsequently, 0.02% collagenase type 4
(Sigma-Aldrich) and 5 mM CaCl2 were added to the basic liver
perfusion buffer and perfusion was continued until digestion was
complete. The digested liver was suspended in 50 ml of PBS and
the dissociated cells were passed through a 100 mm nylon mesh
and centrifuged at 50 g for 5 minutes at 4uC. After centrifugation,
precipitated cells were used as hepatocyte fraction, and 35 ml of
supernatant was transferred to a new tube and washed with PBS.
Cells were centrifuged at least twice at 2000 rpm for 5 minutes
and the pellets were suspended in ice-cold PBS containing 10%
FBS and used as non-parenchymal cells.
Flow Cytometry Analysis and Sorting
Aliquots of non-parenchymal cells were incubated with red
blood cell lysis buffer (Sigma-Aldrich) to eliminate erythrocytes.
After washing with PBS, cells were blocked with 10% rat serum
(eBioscience) in PBS for 30 minutes on ice. Cells were then
incubated with fluorescence-conjugated EpCAM (eBioscience) and
F4/80 (eBioscience) antibodies in 3% BSA/PBS for 30 minutes on
ice, sorted using FACSVantageSE DiVa (BD Biosciences), and
analyzed using FlowJo software.
Culture of Sorted Cells
EpCAM-positive (EpCAM
+) cells sorted from non-parenchymal
liver cells were suspended in Williams’ medium E supplemented
with 10% FBS, 2 mM L-glutamine, 100 nM dexamethasone,
16ITS (insulin, transferrin, selenium X), 10 ng/ml human
epidermal growth factor (hEGF), and 10 ng/ml human hepato-
cyte growth factor (hHGF). Cells were seeded on Matrigel (BD
Biosciences) and cultured in 37uCC O 2 incubator.
RNA Extraction and Quantitative Real-time Reverse
Transcription PCR (RT-PCR)
Total RNA was extracted using RNeasy Mini Kit (QIAGEN,
Germantown, MD) according to the manufacturer’s instruction.
Total RNA and oligo dT primer were used to synthesize cDNA
using the Superscript III RT (Invitrogen). Quantitative real-time
RT-PCR was performed using the MX3000 Real-Time PCR
System (Stratagene, Santa Clara, CA). PCR primers for mouse
genes are listed in Table S1. Target cDNAs were normalized to
endogenous mRNA levels of the housekeeping reference gene 18s
ribosomal RNA (18s rRNA). The reproducibility of this quantification
method was examined by comparing results obtained from
replicate samples during the same reaction run with those from
independent runs on different days. The PCR reactions were
performed at least 3 times for each sample. Data are presented as
Hepatic Stem Cell Activation in DDB1 Mutant Mice
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31846means and standard errors of the mean (SEMs). Statistical
significance was assessed with Student t test.
Microarray
Sample amplification, labeling and hybridization on Illumina
GeneChip Mouse Genome 48K Arrays were performed for all
arrays in this study according to the manufacturer’s instructions
(Illumina, Inc., San Diego, CA) using an Illumina BeadStation in
the Burnham Institute’s Microarray Core Facility. Total RNA
samples were prepared in RNeasy Mini Kit (QIAGEN) from
isolated EpCAM
+ cells from DDB1
F/F;Alb-Cre
+/+ or DDC-treated
wild type liver, and compared with hepatocytes isolated from wild
type liver. Data analysis was done in three stages. First, expression
intensities were calculated for each gene probed on the array for
all hybridizations using the algorithm supplied with the illumina
GenomeStudio software. Second, intensity values were quality
controlled and normalized: quality control was carried out by
using the detection P-value with a cutoff of 0.05. Genes with a P-
value only ever above this were removed from the analysis. All the
arrays were then normalized using the bioconductor normalize.
quantiles. This procedure accounted for any variation in hybrid-
ization intensity between the individual arrays. These normalized
data were imported into GeneSpring and analysed for differen-
tially expressed genes on the basis of fold change (.26).
Microarray data were deposited in the GEO database (accession
number GSE31588) and followed MIAME requirements.
Liver Function Assays
Blood samples collected from mice were analyzed using a
mammalian liver enzyme profile rotor on a VetScan VS2 analyzer
(Abaxis, Union City, CA).
Statistical analysis
Differences in real-time PCR data were analyzed by one-way
ANOVA followed by Bonferroni post-hoc test. GraphPad Prism
software was used for statistical analysis of these data. P,0.05 and
P,0.01 were considered as statistically significant and highly
significant respectively.
Results
Hepatocyte-specific deletion of DDB1 induces ductal cell
proliferation
We previously reported that DDB1 is required for hepatocyte
replication, and hepatocyte-specific deletion of DDB1 leads to
regeneration of new DDB1-expressing hepatocytes [17]. To
determine the origin of these regenerated DDB1-expressing
hepatocytes, we generated DDB1
F/F;Alb-Cre
+/+ mouse, in which
homozygous copies of Alb-Cre would allow for maximal Cre
expression and thus more effective deletion of DDB1. We found
that the liver from DDB1
F/F;Alb-Cre
+/+ mice appeared pale with
rough surface between 2 and 3 weeks of age, but small pink
regenerative nodules began to emerge from white patches around
4 weeks of age (Figure S1A). H&E staining of the liver sections
from 4-week-old mutants revealed massive periportal expansion of
small cells that form interconnected ductal structures (Figure 1A).
IHC staining for DDB1 demonstrated that DDB1-expressing
small cells and hepatocytes are embedded in numerous DDB1-
depleted hepatocytes (Figure 1B), after nearly complete lose of
DDB1 expression in hepatocytes by three weeks of age (Figure
S1B). These DDB1-expressing small cells are generally located
adjacent to the portal veins and multiply (Figure S1C), and can be
found in the liver from 3-week-old mutant mice prior to the
appearance of DDB1
+ hepatocyte nodules.
DDB1-expressing small cells in the liver are oval cells
Failure of hepatocyte proliferation or severe liver damage results
in activation of HSCs and OCs [9]. OCs are believed to take the
form of the ductal reaction and are able to generate new
hepatocytes to replace damaged hepatocytes. Morphologically
DDB1-expressing ductal cells in DDB1
F/F;Alb-Cre
+/+ liver resemble
OCs, with oval nuclei and scant cytoplasm content. To verify that
these cells are OCs, we performed IF staining for the OC
biomarker A6 [20,21], and found that these DDB1-expressing
ductal cells co-expressed A6 (Figure 1C). Generally these cells
appeared adjacent to the portal veins and infiltrated the
parenchyma surrounding the DDB1-positive regenerative nodules.
In contrast, cells expressing A6 in DDB1
F/F liver were rare and
restricted to normal bile duct epithelial cells. These ductal cells
from the DDB1 mutant mice expressed a cholangiocyte marker
Ck19 but not hepatocyte marker Albumin (Figure 2A). To identify
the cell surface molecules expressed on these cells, we performed
staining for additional stem or progenitor cell markers [22]. We
found that these cells are positive for E-cadherin, CD133 and
some cells are positive for AFP (Figure 2A). Taken together, these
observations suggest that deletion of DDB1 in hepatocytes induces
OC proliferation, judged from these cells’ morphology, physical
location and biomarker expression.
Oval cells are activated in other DDB1 mutant mouse
strains
EpCAM is expressed in cholangiocytes but not in hepatocytes in
normal liver, and it is a well-established marker for proliferating
OCs [23]. To determine whether EpCAM is expressed in our
mouse model, we performed EpCAM and A6 double IF staining
on liver sections from 4 week-old DDB1
F/F;Alb-Cre
+/+ mice. We
found that numerous A6-positive ductal cells were also positive for
EpCAM (Figure 2B). Less prominent activation of A6
+ EpCAM
+
OCs was observed in the liver of DDB1
F/F;Alb-Cre
+/2 mice at 6
weeks of age, when DDB1-expressing hepatocytes are actively
replacing DDB1-deficient hepatocytes (Figure 2C) [17]. An
inducible model, DDB1
F/F;Mx1-Cre
+/2 adult mice [17] also
exhibited numerous ductal cells expressing both A6 and EpCAM
when new hepatocytes were regenerated 6 weeks after receiving
injection of poly(I:C) (Figure 2D). Taken together, these findings
indicate that both constitutive and inducible DDB1 deletion in
hepatocytes results in OC proliferation.
Deletion of p21 partially restores proliferation of DDB1-
deficient hepatocytes and alleviates OC activation
We previously reported that DDB1-deficient hepatocytes
accumulate cell cycle inhibitor p21, a substrate of DDB1 ubiquitin
ligase [24,25], and fail to proliferate during liver growth or after
partial hepatectomy [17]. Similarly, hepatocytes from DDB1
F/F;
Alb-Cre
+/+ mice express high levels of p21, but not Cdt1
(Figure 3A), another substrate of the E3 ligase [16]. p21 is
dramatically enriched in the nuclear fraction of DDB1-depleted
MEFs [19] (Figure 3B), consistent with a role of p21 in blocking
proliferation of these cells. Indeed, deletion of p21 abrogates the
cell cycle arrest of cells with inactivated Cul4A-DDB1 ubiquitin
ligase [25,26]. We therefore generated compound mutant mice by
crossing DDB1
F/F;Alb-Cre
+/2 mice and p21
2/2 mice [27].
Deletion of p21 in DDB1
F/F;Alb-Cre
+/2 mice allowed DDB1-
decificent hepatocytes to proliferate (Figure 3C), resulting in
significantly less compensatory proliferation of DDB1-expressing
OCs (Figure 3D). However, p21 deletion did not fully reverse the
proliferative arrest of DDB1-deficient hepatocytes (data not
shown). These hepatocytes may still have other defects such as
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ligase activity [28,29,30]. We conclude that failed proliferation of
DDB1-deficient hepatocytes is responsible for activation of DDB1-
expressing OCs.
EpCAM-positive cells in DDB1 mutant form colonies in
vitro and repopulate the liver in vivo
To characterize these OCs, we perfused the liver of DDB1
F/F;
Alb-Cre
+/+ mice, separated non-parenchymal cells from hepato-
cytes, and isolated EpCAM
+ and F4/80
2 cells by FACS. We
typically harvested around 13% of EpCAM
+ cells from the non-
parenchymal cell fraction prepared from the mutant liver, but
harvested barely any such cells from age-matched wild type liver
(Figure 4A). When cultured on Matrigel-coated plates, these
cells formed colonies and retained EpCAM expression
(Figure 4B). Even after one month in culture, cells in the
colonies still express A6 and AFP (Figure 4C), resembling those
OCs in vivo.
Regeneration of new hepatocytes to repair injured liver is a
pivotal function for hepatic stem/progenitor cells. It was
previously reported that OCs isolated from mouse liver could
reconstitute hepatic tissues after transplantation into mice with
injured liver [13,31]. To determine whether OCs isolated from
DDB1 mutant liver can give rise to new hepatocytes in vivo,w e
crossed DDB1
F/F;Mx1-Cre
+/2 mice with a Rosa26-lacZ Cre-
reporter mouse strain [18]. We isolated EpCAM
+ cells by FACS
from DDB1
F/F;Mx1-Cre
+/2;Rosa26-lacZ mice that had been
injected with poly(I:C), and then injected these cells intrasplen-
ically into nude mice (Figure 4D, E). Prior to cell transplantation,
the recipient nude mice had been preconditioned with DDC diet
Figure 1. Deletion of DDB1 in hepatocytes results in hepatic oval cells activation. (A)H&Estainingof liver sectionsfrom4-weekoldDDB1
F/F
and DDB1
F/F;Alb-Cre
+/+ mice. PV, portal vein. (B) IHC staining for DDB1 on liver sections from 4-week old DDB1
F/F and DDB1
F/F;Alb-Cre
+/+ mice. (C) Co-IF
staining for DDB1 and A6 on 4-week old DDB1
F/F and DDB1
F/F;Alb-Cre
+/+ liver sections.
doi:10.1371/journal.pone.0031846.g001
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were sacrificed 2 weeks after injection of EpCAM
+ cells and, one
day before sacrificing, received one i.p. injection of poly(I:C) to
activate LacZ expression specifically from donor cells. IHC
staining on these liver sections showed many ß-gal-positive
hepatocytes (Figure 4F), suggesting that the transplanted
EpCAM
+ OCs differentiated into hepatocytes in the recipient
liver.
DDB1 mutant mice exhibit minor liver damage compared
with DDC-treated mice
To determine the severity of liver damage in the DDB1 mutant
mice, we compared 4-week old DDB1
F/F;Alb-Cre
+/+ mice with a
conventional chemical injury model for OC proliferation, mice
treated with diet containing 3,5-diethoxycarbonyl-1,4-dihydro-
collidine (DDC). Consistent with previous reports [13,32,33],
ductal cells from DDC-treated wild type mice expressed both A6
Figure 2. Expression of oval cell markers in DDB1 mutant mouse liver. (A) Co-IF staining for Cytokeratin-19 (CK19) and Albumin (Alb) (upper
panels), E-cadherin and DDB1 (middle panels), a-fetoprotein (AFP) and CD133 (lower panels). (B–D) Co-IF staining for EpCAM and A6 on liver sections
from 4-week old DDB1
F/F;Alb-Cre
+/+ (B), 6-week old DDB1
F/F;Alb-Cre
+/2 (C), and adult DDB1
F/F;Mx1-Cre
+/2 mice at 6 weeks after receiving poly(I:C)
injection (D).
doi:10.1371/journal.pone.0031846.g002
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weeks, their livers turned dark brown (Figure 5B), due to hepatic
porphyria resulting from the inhibition of the heme biosynthetic
pathway [34]. H&E staining showed some ductal cells around the
portal veins with brown metabolite deposits (Figure 5C). To
characterize the extent of liver inflammation, we performed CD45
and F4/80 staining for leukocytes and macrophages, respectively.
In liver sections from DDC-treated mice, we found greatly
enriched CD45
+ and F4/80
+ cells surrounding OCs (Figure 5D).
In contrast, DDB1
F/F;Alb-Cre
+/+ mouse liver did not show
significant increase of these immune cells compared with
DDB1
F/F liver (Figure 5D), even though there are more OCs in
the DDB1 mutant liver than DDC mice (Figure 5E). We further
measured the severity of liver damage by serum alanine
Figure 3. Deletion of p21 partially restores proliferation of DDB1-deficient hepatocytes and alleviates OC activation. (A) Western blot
for some substrates of DDB1-Cul4A ubiquitin ligase using lysates of hepatocytes isolated from DDB1
F/F and DDB1
F/F;Alb-Cre
+/+ mice. (B) Western blot
for DDB1 and p21 using lysates of cytoplasmic fraction (C) and nuclear fraction (N) prepared from MEFs. (C) IHC staining for DDB1 and Ki67 on liver
sections from DDB1
F/F;Alb-Cre
+/2, DDB1
F/F;p21
2/2 and DDB1
F/F;Alb-Cre
+/2;p21
2/2 mice. (D) Co-IF staining for A6 and DDB1 on DDB1
F/F;p21
2/2 and
DDB1
F/F;Alb-Cre
+/2;p21
2/2 liver sections. Arrows in DDB1
F/F;Alb-Cre
+/2;p21
2/2 mice indicate A6 positive oval cells.
doi:10.1371/journal.pone.0031846.g003
Hepatic Stem Cell Activation in DDB1 Mutant Mice
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31846aminotransferase (ALT) assays. The ALT level in the DDB1
mutant mice was 191673 (IU/L); however, it was nearly 10 times
higher, reaching 16796475 (IU/L) (normal range: 28–132 U/L)
in the DDC-treated mice (Figure 5F), consistent with the overall
toxicity of DDC to the liver. With seemingly insignificant damage
to hepatocytes, our genetic model provides a better system for
studying HSC and OC biomarkers and their extracellular
activation signals.
Characterization of OCs from DDB1 mutant mice
Since OCs from our DDB1 mutant mice have not been exposed
to promiscuous chemical damage, we decided to identify new OC
biomarkers that might have been masked in chemical injury
models. EpCAM
+ cells were isolated from DDB1
F/F;Alb-Cre
+/+
mice and from DDC-treated mice, and their gene expression
profiles were analyzed with Illumina genechips (Table S2). Wild
type hepatocytes were purified and used as a control. EpCAM
+
Figure 4. EpCAM-positive cells from DDB1 mutant liver proliferate in vitro and repopulate the liver in vivo. (A) Analysis by flow
cytometry of EpCAM
+ F4/80
2 cells in non-parenchymal fractions prepared from 4-week old DDB1
F/F and DDB1
F/F;Alb-Cre
+/+ mice. The ratio of EpCAM
+
F4/80
2 cells from a representative experiment is shown in each panel. (B) In vitro culture of EpCAM
+ cells sorted by FACS from DDB1 mutant liver and
seeded on Matrigel. Cells form colonies after 1, 3, and 9 days of culture (upper panels) and exhibit EpCAM positivity (lower panels). (C) Co-IF staining
for A6 and AFP on colonies from cultured EpCAM
+ cells. (D) Experimental scheme for in vivo differentiation of EpCAM
+ OCs. Adult DDB1
F/F;Mx1-Cre
+/2;
Rosa26-lacZ mice were generated and injected with poly(I:C). EpCAM
+ cells were isolated by FACS 6 weeks later, and injected intrasplenically to nude
mice that had been fed with DDC diet. The recipient nude mice received poly(I:C) injection 2 weeks later and liver collected for analysis on the
following day. (E) Isolation of EpCAM
+ F4/80
2 cells from donor or control mouse liver. The ratio of EpCAM
+ F4/80
2 cells is shown in each panel.
(F) IHC staining for ß-gal on liver sections from recipient nude mice. Arrows indicate positively stained hepatocytes.
doi:10.1371/journal.pone.0031846.g004
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OC markers such as Cldn4, Itgb4, Dmbt1, Ck19, Ncam1,
Cd24a, Connexin43 [35,36]. These cells also express hemato-
poietic stem cell markers such as Sca-1 and Cd44, but not Cd34
or C-kit. Fn14 receptor, encoded by Tnfrsf12a, is upregulated in
OCs, agreeing with the reported role of TWEAK/Fn14 in OC
proliferation [14]. Recently, Sox-9 was reported as a marker for
progenitor cell population and contributes to the self renewal and
repair of the adult liver [37]. We found Sox-9 is also highly
upregulated in OCs.
Figure 5. DDB1 mutant mice exhibit minor liver damage compared with DDC-treated mice. (A): Co-IF staining for A6 and EpCAM on liver
sections from DDC-treated mice. (B): Gross appearance of liver from mice fed with DDC diet for 4 weeks. (C): H&E staining of the liver in (B). (D): IHC
staining for CD45 (upper panels) and F4/80 (lower panels) on liver sections from DDB1
F/F, DDB1
F/F;Alb-Cre
+/+ and DDC-treated mice. (E): Percentage of
EpCAM
+ cells from DDB1
F/F;Alb-Cre
+/+ and DDC-diet liver, determined by FACS analysis. Data are representative of 4 independent experiments with 3
mice per group in each experiment. Values are expressed as the means6SEM; n=3. (F): Serum alanine aminotransferase (ALT) levels. Data are
representative of 4 independent experiments with 3 mice per group in each experiment. Values are expressed as means6SEM; n=3 **P,0.01.
doi:10.1371/journal.pone.0031846.g005
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profiling. Expression levels of candidate genes including Sca1,
Thy1, Cd44, CD133, Connexin43 and Ncam1 are all confirmed to be
increased (Figure 6A) [35,38,39]. As expected, OCs from both
models expressed cholangiocyte markers (Ck19, Spp1), but not
hepatocyte marker (Alb) (Figure 6B). Therefore, OCs from the
DDB1 mutant mouse model are generally similar to the cells
isolated from a conventional injury model. Though many genes
are upregulated in both models, several previously unrecognized
genes have been found to be upregulated only in OCs from DDB1
mutant mice. To search for new stem/progenitor markers masked
in chemical models, we analyzed genes that are specifically
enriched in OCs isolated from the DDB1 mutant liver in
comparison with OCs from DDC-treated liver. Three candidate
genes, Reelin, endothelin receptor type B (EdnrB), Cd206 (also
known as MRC1, mannose receptor, C type 1) were identified and
confirmed by quantitative real-time PCR (Figure 6C). Reelin, an
extracellular matrix protein, controls neuronal migration during
embryonic brain development [40]. Reelin was reported to be
expressed in activated hepatic stellate cells [41]. We found Reelin
was abundant in OCs in DDB1 mutant liver (Figure 6D). Further
experiments are required to determine biomarker or functional
properties of Reelin and the other 2 candidate genes in HSC
activation and OC proliferation.
Discussion
It has been claimed for decades that HSCs can be activated and
contribute to liver regeneration when hepatocyte proliferation is
compromised.Supports from this claim mostly come from studies of
rodents treated with chemicals that intoxicate the liver. Here we
provide direct evidence that targeted deletion of DDB1 in
hepatocytes blocks replication of these cells and as a consequence
quiescent HSCs and OCs proliferate in a compensatory regener-
ation process. Unlike chemicals, genetic ablation of DDB1 is
restricted to hepatocytes and leaves intact non-parenchymal cells
including HSCs and OCs. Therefore this model is ideal for
dissecting the extracellular signals that mediate the cross-talks
between damaged hepatocytes and activated HSCs. For example,
our array data indicate that Fn14, a TWEAK receptor, is up-
regulated in EpCAM
+ OCs. Our next step will be to determine the
cellular origin of TWEAK, either being DDB1-deficient hepato-
cytes or being newly regenerated DDB1-expressing hepatocytes.
Since we have not performed genetic tracing on these models,
we cannot conclude that all DDB1-positive hepatocytes come from
HSCs. Though deletion of DDB1 is quite complete, we cannot
rule out that a few hepatocytes escape Cre-mediated deletion and
thus contribute to the pool of new hepatocytes. However, it is clear
that initial hepatocyte proliferation is essential for HSCs
activation. Interestingly, completely blocking regeneration of
DDB1-expressing hepatocytes, which can be achieved by frequent
injections of poly(I:C) to DDB1
F/F;Mx1-Cre
+/2 mice results in
almost no activation of OCs (Endo and Cang, unpublished data).
This observation suggests that newly regenerated hepatocytes
might provide paracrine factors critical for either activation of
HSCs or proliferation of OCs.
Another advantage of the DDB1 model over the injury model is
that these genetic mutant mice exhibit much milder liver damage
during the course of HSC-driven liver regeneration, although both
models produce OCs expressing similar markers (Fig. 5) that are
also reported in OCs from other models [35,42,43]. We therefore
performed microarray analysis of EpCAM
+ oval cells isolated from
the DDB1 mutant mice, and hoped to unravel novel biomarkers
that are suppressed in the severely damaged liver of conventional
injury rodents. Indeed, we identified three candidate genes, Reelin,
EdnrB, and Cd206, which are up-regulated only in OCs from the
DDB1 mutant mice. These genes were not expressed in OCs from
the injury models and have not been reported as OC markers.
Whether these genes have functional roles in HSC activation and
OC proliferation or simply are biomarkers still awaits investigation.
We present two mouse genetic models that bypass the hurdles to
work with the prevailing injury models. In DDB1
F/F;Mx1-Cre
+/2
mice, HSCs can be repeatedly induced by poly(I:C) injection to
generate transit-amplifying oval cells and new hepatocytes, both
expressing DDB1 and therefore clearly distinct from DDB1-
depleted old hepatocytes. In DDB1
F/F;Alb-Cre
+/2 or DDB1
F/F;Alb-
Cre
+/+ mice, DDB1-depeleted hepatocytes are continuously
replaced by new DDB1-expressing hepatocyte generated by
HSCs. The high rate of hepatocyte turnover driven by HSCs in
the mutant liver, in contrast to a very slow turnover rate in normal
liver [37], is reminiscent of highly proliferative tissue such as skin
and intestine in which stem cells continually generate progeny with
diminished replicative capacity. These two models will allow us to
trace the origin and differentiation of HSCs as well as perform
genetic assessment of signalling pathways important for regulating
this mysterious population of cells in the liver.
Supporting Information
Figure S1 Deletion of DDB1 in hepatocytes results in
ductal cell proliferation. (A) Gross appearance of livers
dissected from 4-week old DDB1
F/F and DDB1
F/F;Alb-Cre
+/+ mice.
(B) IHC staining for DDB1 on liver sections from 3-week old
DDB1
F/F;Alb-Cre
+/+ mice. Arrows indicate DDB1-positive small
cells. (C) DDB1 positive ductal cells (left panel) express Ki-67 (right
panel).
(TIF)
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Figure 6. Characterization of OCs from DDB1 mutant mice and DDC-treated mice. (A–C): Quantitative real-time PCR analysis for selected
genes expressed in hepatocytes isolated from wild type mice, and EpCAM
+ cells isolated from DDC-treated and DDB1
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+/+ mice. All data are
normalized to 18s rRNA level. Data are representative of 4 independent experiments with 3–4 mice per group. *P,0.05 (A): Expression levels of
hematopoietic markers Sca1, Thy1 and Cd44, and OC markers CD133, Connexin43 and Ncam1.( B): Expression levels of cholangiocyte marker Ck19 and
Spp1, and hepatocyte marker Alb.( C): Expression levels of candidate OC markers, Reelin, EdnrB and Cd206. (D): IHC staining for reelin on liver sections
from DDB1
F/F, DDB1
F/F;Alb-Cre
+/+ and DDC-treated mice. Arrows in DDC-treated liver indicate non-specific brown deposits.
doi:10.1371/journal.pone.0031846.g006
Hepatic Stem Cell Activation in DDB1 Mutant Mice
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e31846References
1. Slack JM (2008) Origin of stem cells in organogenesis. Science 322: 1498–1501.
2. Blanpain C, Fuchs E (2009) Epidermal homeostasis: a balancing act of stem cells
in the skin. Nat Rev Mol Cell Biol 10: 207–217.
3. Michalopoulos GK, DeFrances MC (1997) Liver regeneration. Science 276:
60–66.
4. Taub R (2004) Liver regeneration: from myth to mechanism. Nat Rev Mol Cell
Biol 5: 836–847.
5. Fausto N, Campbell JS, Riehle KJ (2006) Liver regeneration. Hepatology 43:
S45–53.
6. Sell S (2001) Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology
33: 738–750.
7. Fausto N (2004) Liver regeneration and repair: hepatocytes, progenitor cells, and
stem cells. Hepatology 39: 1477–1487.
8. Zaret KS, Grompe M (2008) Generation and regeneration of cells of the liver
and pancreas. Science 322: 1490–1494.
9. Duncan AW, Dorrell C, Grompe M (2009) Stem cells and liver regeneration.
Gastroenterology 137: 466–481.
10. Alison MR, Islam S, Lim S (2009) Stem cells in liver regeneration, fibrosis and
cancer: the good, the bad and the ugly. J Pathol 217: 282–298.
11. Laishes BA, Rolfe PB (1981) Search for endogenous liver colony-forming units in
F344 rats given a two-thirds hepatectomy during short-term feeding of 2-
acetylaminofluorene. Cancer Res 41: 1731–1741.
12. Akhurst B, Croager EJ, Farley-Roche CA, Ong JK, Dumble ML, et al. (2001) A
modified choline-deficient, ethionine-supplemented diet protocol effectively
induces oval cells in mouse liver. Hepatology 34: 519–522.
13. Wang X, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, et al. (2003) The
origin and liver repopulating capacity of murine oval cells. Proc Natl Acad
Sci U S A 100 Suppl 1: 11881–11888.
14. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, et al. (2005)
TWEAK induces liver progenitor cell proliferation. J Clin Invest 115:
2330–2340.
15. Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, et al. (2010) Nf2/
Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes
Dev 24: 1718–1730.
16. Jackson S, Xiong Y (2009) CRL4s: the CUL4-RING E3 ubiquitin ligases.
Trends Biochem Sci.
17. Yamaji S, Zhang M, Zhang J, Endo Y, Bibikova E, et al. (2010) Hepatocyte-
specific deletion of DDB1 induces liver regeneration and tumorigenesis. Proc
Natl Acad Sci U S A 107: 22237–22242.
18. Soriano P (1999) Generalized lacZ expression with the ROSA26 Cre reporter
strain. Nat Genet 21: 70–71.
19. Cang Y, Zhang J, Nicholas SA, Bastien J, Li B, et al. (2006) Deletion of DDB1 in
mouse brain and lens leads to p53-dependent elimination of proliferating cells.
Cell 127: 929–940.
20. Factor VM, Radaeva SA (1993) Oval cells–hepatocytes relationships in Dipin-
induced hepatocarcinogenesis in mice. Exp Toxicol Pathol 45: 239–244.
21. Engelhardt NV, Factor VM, Medvinsky AL, Baranov VN, Lazareva MN, et al.
(1993) Common antigen of oval and biliary epithelial cells (A6) is a
differentiation marker of epithelial and erythroid cell lineages in early
development of the mouse. Differentiation 55: 19–26.
22. Mishra L, Banker T, Murray J, Byers S, Thenappan A, et al. (2009) Liver stem
cells and hepatocellular carcinoma. Hepatology 49: 318–329.
23. Balzar M, Winter MJ, de Boer CJ, Litvinov SV (1999) The biology of the 17-1A
antigen (Ep-CAM). J Mol Med 77: 699–712.
24. Abbas T, Sivaprasad U, Terai K, Amador V, Pagano M, et al. (2008) PCNA-
dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2
ubiquitin ligase complex. Genes Dev 22: 2496–2506.
25. Kim Y, Starostina NG, Kipreos ET (2008) The CRL4Cdt2 ubiquitin ligase
targets the degradation of p21Cip1 to control replication licensing. Genes Dev
22: 2507–2519.
26. Liu L, Lee S, Zhang J, Peters SB, Hannah J, et al. (2009) CUL4A abrogation
augments DNA damage response and protection against skin carcinogenesis.
Mol Cell 34: 451–460.
27. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, et al. (1995)
Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:
552–557.
28. Braun S, Garcia JF, Rowley M, Rougemaille M, Shankar S, et al. (2011) The
Cul4-Ddb1(Cdt)(2) ubiquitin ligase inhibits invasion of a boundary-associated
antisilencing factor into heterochromatin. Cell 144: 41–54.
29. Oda H, Hubner MR, Beck DB, Vermeulen M, Hurwitz J, et al. (2010)
Regulation of the histone H4 monomethylase PR-Set7 by CRL4(Cdt2)-
mediated PCNA-dependent degradation during DNA damage. Mol Cell 40:
364–376.
30. Tardat M, Brustel J, Kirsh O, Lefevbre C, Callanan M, et al. (2010) The histone
H4 Lys 20 methyltransferase PR-Set7 regulates replication origins in
mammalian cells. Nat Cell Biol 12: 1086–1093.
31. Yovchev MI, Grozdanov PN, Zhou H, Racherla H, Guha C, et al. (2008)
Identification of adult hepatic progenitor cells capable of repopulating injured
rat liver. Hepatology 47: 636–647.
32. Suzuki A, Sekiya S, Onishi M, Oshima N, Kiyonari H, et al. (2008) Flow
cytometric isolation and clonal identification of self-renewing bipotent hepatic
progenitor cells in adult mouse liver. Hepatology 48: 1964–1978.
33. Okabe M, Tsukahara Y, Tanaka M, Suzuki K, Saito S, et al. (2009) Potential
hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver.
Development 136: 1951–1960.
34. Fonia O, Weizman R, Coleman R, Kaganovskaya E, Gavish M (1996) PK
11195 aggravates 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced hepatic
porphyria in rats. Hepatology 24: 697–701.
35. Yovchev MI, Grozdanov PN, Joseph B, Gupta S, Dabeva MD (2007) Novel
hepatic progenitor cell surface markers in the adult rat liver. Hepatology 45:
139–149.
36. Ochsner SA, Strick-Marchand H, Qiu Q, Venable S, Dean A, et al. (2007)
Transcriptional profiling of bipotential embryonic liver cells to identify liver
progenitor cell surface markers. Stem Cells 25: 2476–2487.
37. Furuyama K, Kawaguchi Y, Akiyama H, Horiguchi M, Kodama S, et al. (2011)
Continuous cell supply from a Sox9-expressing progenitor zone in adult liver,
exocrine pancreas and intestine. Nat Genet 43: 34–41.
38. Van Den Heuvel MC, Slooff MJ, Visser L, Muller M, De Jong KP, et al. (2001)
Expression of anti-OV6 antibody and anti-N-CAM antibody along the biliary
line of normal and diseased human livers. Hepatology 33: 1387–1393.
39. Rountree CB, Barsky L, Ge S, Zhu J, Senadheera S, et al. (2007) A CD133-
expressing murine liver oval cell population with bilineage potential. Stem Cells
25: 2419–2429.
40. Rice DS, Curran T (2001) Role of the reelin signaling pathway in central
nervous system development. Annu Rev Neurosci 24: 1005–1039.
41. Kobold D, Grundmann A, Piscaglia F, Eisenbach C, Neubauer K, et al. (2002)
Expression of reelin in hepatic stellate cells and during hepatic tissue repair: a
novel marker for the differentiation of HSC from other liver myofibroblasts.
J Hepatol 36: 607–613.
42. Kofman AV, Morgan G, Kirschenbaum A, Osbeck J, Hussain M, et al. (2005)
Dose- and time-dependent oval cell reaction in acetaminophen-induced murine
liver injury. Hepatology 41: 1252–1261.
43. Preisegger KH, Factor VM, Fuchsbichler A, Stumptner C, Denk H, et al. (1999)
Atypical ductular proliferation and its inhibition by transforming growth factor
beta1 in the 3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic
alcoholic liver disease. Lab Invest 79: 103–109.
Hepatic Stem Cell Activation in DDB1 Mutant Mice
PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e31846